GlassScriptPhysician profile
James Willis Fitzpatrick
NPI 1760475859
$3,535.81
in general payments reported to CMS, 2019-2025
40 companies · $936 in 2025
The $936 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $33.12 · 2021: $356 · 2022: $482 · 2023: $962 · 2024: $603 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $412.88 | 2019-2025 | Evenity, Prolia, Tepezza |
| Medtronic, INC. | $338.78 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $303.88 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Xeris Pharmaceuticals, INC. | $236.13 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $204.80 | 2022-2025 | Jardiance, Lyumjev, Baqsimi |
| Insulet Corporation | $196.84 | 2024-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $192.55 | 2022-2025 | |
| Abbvie INC. | $170.78 | 2022-2024 | |
| Esperion Therapeutics, INC. | $154.94 | 2021-2023 | Nexletol |
| Corcept Therapeutics | $121.85 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.27 | 2023-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $89.86 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $82.72 | 2023-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $82.39 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Mannkind Corporation | $81.71 | 2023-2025 | Afrezza |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.